Malignant blue nevus: Clinicopathologically similar to melanoma

Swapnil Dilip Kachare, Steven Agle, Zachary P. Englert, Emmanuel E. Zervos, Nasreen A. Vohra, Jan H. Wong, Timothy L. Fitzgerald

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Malignant blue nevus (MBN) is a rare melanocytic lesion and controversy exists whether it is a melanoma or a unique entity. We sought to establish clinical behavior using a large national registry. All patients with MBN and melanoma from 1973 to 2008 were identified in the Surveillance Epidemiology and End Results tumor registry. We performed comparative and survival analysis among the two tumor types. A total of 228,038 patients were identified (227,986 with melanoma and 52 with MBN). The mean age was 57.7 years. Both lesions had similar age of presentation (55.8 vs 55.7 years, P = 0.527), sex (male 50 vs 55%, P = 0.44), and nodal positivity rate (9.6 vs 5.4%, P = 0.22). MBNs were more likely to be nonwhite (11.8 vs 1.6%, P <0.0001) and present with metastatic disease (15.2 vs 4%, P = 0.0028). MBN and melanoma had a similar survival (264 vs 240 months, P = 0.78) and remained similar when stratified by race (264 vs 242 months, P = 0.99) and stage (264 vs 256 months, P = 0.83). This is the largest study to date demonstrating similar clinical behavior and survival between patients with MBN and those with melanoma. We believe MBN is a variant of melanoma and suggest using a similar treatment algorithm as that of melanoma. Copyright Southeastern Surgical Congress. All rights reserved.

Original languageEnglish (US)
Pages (from-to)651-656
Number of pages6
JournalThe American surgeon
Volume79
Issue number7
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Blue Nevus
Melanoma
Nevi and Melanomas
Registries
Survival
Survival Analysis
Neoplasms
Epidemiology

ASJC Scopus subject areas

  • Surgery

Cite this

Kachare, S. D., Agle, S., Englert, Z. P., Zervos, E. E., Vohra, N. A., Wong, J. H., & Fitzgerald, T. L. (2013). Malignant blue nevus: Clinicopathologically similar to melanoma. The American surgeon, 79(7), 651-656.

Malignant blue nevus : Clinicopathologically similar to melanoma. / Kachare, Swapnil Dilip; Agle, Steven; Englert, Zachary P.; Zervos, Emmanuel E.; Vohra, Nasreen A.; Wong, Jan H.; Fitzgerald, Timothy L.

In: The American surgeon, Vol. 79, No. 7, 07.2013, p. 651-656.

Research output: Contribution to journalArticle

Kachare, SD, Agle, S, Englert, ZP, Zervos, EE, Vohra, NA, Wong, JH & Fitzgerald, TL 2013, 'Malignant blue nevus: Clinicopathologically similar to melanoma', The American surgeon, vol. 79, no. 7, pp. 651-656.
Kachare SD, Agle S, Englert ZP, Zervos EE, Vohra NA, Wong JH et al. Malignant blue nevus: Clinicopathologically similar to melanoma. The American surgeon. 2013 Jul;79(7):651-656.
Kachare, Swapnil Dilip ; Agle, Steven ; Englert, Zachary P. ; Zervos, Emmanuel E. ; Vohra, Nasreen A. ; Wong, Jan H. ; Fitzgerald, Timothy L. / Malignant blue nevus : Clinicopathologically similar to melanoma. In: The American surgeon. 2013 ; Vol. 79, No. 7. pp. 651-656.
@article{ecad341cce874963bf22f5e0cdd3f7ca,
title = "Malignant blue nevus: Clinicopathologically similar to melanoma",
abstract = "Malignant blue nevus (MBN) is a rare melanocytic lesion and controversy exists whether it is a melanoma or a unique entity. We sought to establish clinical behavior using a large national registry. All patients with MBN and melanoma from 1973 to 2008 were identified in the Surveillance Epidemiology and End Results tumor registry. We performed comparative and survival analysis among the two tumor types. A total of 228,038 patients were identified (227,986 with melanoma and 52 with MBN). The mean age was 57.7 years. Both lesions had similar age of presentation (55.8 vs 55.7 years, P = 0.527), sex (male 50 vs 55{\%}, P = 0.44), and nodal positivity rate (9.6 vs 5.4{\%}, P = 0.22). MBNs were more likely to be nonwhite (11.8 vs 1.6{\%}, P <0.0001) and present with metastatic disease (15.2 vs 4{\%}, P = 0.0028). MBN and melanoma had a similar survival (264 vs 240 months, P = 0.78) and remained similar when stratified by race (264 vs 242 months, P = 0.99) and stage (264 vs 256 months, P = 0.83). This is the largest study to date demonstrating similar clinical behavior and survival between patients with MBN and those with melanoma. We believe MBN is a variant of melanoma and suggest using a similar treatment algorithm as that of melanoma. Copyright Southeastern Surgical Congress. All rights reserved.",
author = "Kachare, {Swapnil Dilip} and Steven Agle and Englert, {Zachary P.} and Zervos, {Emmanuel E.} and Vohra, {Nasreen A.} and Wong, {Jan H.} and Fitzgerald, {Timothy L.}",
year = "2013",
month = "7",
language = "English (US)",
volume = "79",
pages = "651--656",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "7",

}

TY - JOUR

T1 - Malignant blue nevus

T2 - Clinicopathologically similar to melanoma

AU - Kachare, Swapnil Dilip

AU - Agle, Steven

AU - Englert, Zachary P.

AU - Zervos, Emmanuel E.

AU - Vohra, Nasreen A.

AU - Wong, Jan H.

AU - Fitzgerald, Timothy L.

PY - 2013/7

Y1 - 2013/7

N2 - Malignant blue nevus (MBN) is a rare melanocytic lesion and controversy exists whether it is a melanoma or a unique entity. We sought to establish clinical behavior using a large national registry. All patients with MBN and melanoma from 1973 to 2008 were identified in the Surveillance Epidemiology and End Results tumor registry. We performed comparative and survival analysis among the two tumor types. A total of 228,038 patients were identified (227,986 with melanoma and 52 with MBN). The mean age was 57.7 years. Both lesions had similar age of presentation (55.8 vs 55.7 years, P = 0.527), sex (male 50 vs 55%, P = 0.44), and nodal positivity rate (9.6 vs 5.4%, P = 0.22). MBNs were more likely to be nonwhite (11.8 vs 1.6%, P <0.0001) and present with metastatic disease (15.2 vs 4%, P = 0.0028). MBN and melanoma had a similar survival (264 vs 240 months, P = 0.78) and remained similar when stratified by race (264 vs 242 months, P = 0.99) and stage (264 vs 256 months, P = 0.83). This is the largest study to date demonstrating similar clinical behavior and survival between patients with MBN and those with melanoma. We believe MBN is a variant of melanoma and suggest using a similar treatment algorithm as that of melanoma. Copyright Southeastern Surgical Congress. All rights reserved.

AB - Malignant blue nevus (MBN) is a rare melanocytic lesion and controversy exists whether it is a melanoma or a unique entity. We sought to establish clinical behavior using a large national registry. All patients with MBN and melanoma from 1973 to 2008 were identified in the Surveillance Epidemiology and End Results tumor registry. We performed comparative and survival analysis among the two tumor types. A total of 228,038 patients were identified (227,986 with melanoma and 52 with MBN). The mean age was 57.7 years. Both lesions had similar age of presentation (55.8 vs 55.7 years, P = 0.527), sex (male 50 vs 55%, P = 0.44), and nodal positivity rate (9.6 vs 5.4%, P = 0.22). MBNs were more likely to be nonwhite (11.8 vs 1.6%, P <0.0001) and present with metastatic disease (15.2 vs 4%, P = 0.0028). MBN and melanoma had a similar survival (264 vs 240 months, P = 0.78) and remained similar when stratified by race (264 vs 242 months, P = 0.99) and stage (264 vs 256 months, P = 0.83). This is the largest study to date demonstrating similar clinical behavior and survival between patients with MBN and those with melanoma. We believe MBN is a variant of melanoma and suggest using a similar treatment algorithm as that of melanoma. Copyright Southeastern Surgical Congress. All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=84879652090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879652090&partnerID=8YFLogxK

M3 - Article

C2 - 23815995

AN - SCOPUS:84879652090

VL - 79

SP - 651

EP - 656

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 7

ER -